Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Impact of Nutritional Managment on Pregnancy With IBD Patients and Their Springs (IBD/pregnancy)

tiistai 5. toukokuuta 2026 päivittänyt: Amira Mohammed Abdel Mowgod, Assiut University
While diet can support IBD management, with the potential to positively benefit perinatal as well as longer-term health outcomes, little is known about the quality of dietary patterns among pregnant women with IBD , therefore, the objectives of our study are to assess the dietary patterns and diet quality of pregnant women with IBD, and to examine the associations between dietary patterns, diet quality, and dietary guidelines for pregnancy and growth of their offerings

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Yksityiskohtainen kuvaus

Pregnancy is a critical time for the intergenerational transmission of health (. Pregnant women with active inflammatory bowel disease (IBD), a chronic disease characterized by inflammation of the gastrointestinal tract are considered to be at higher risk of poor pregnancy outcomes such as preterm birth, low birthweight or small for gestational age (SGA), spontaneous abortion, and stillbirth, and comprise an increased percentage of Cesarean deliveries compared to women in remission or without IBD. The prevalence of IBD has been increasing worldwide; thus, improving the health of pregnant women with IBD is essential to decreasing their risk for adverse pregnancy outcomes.

A balanced perinatal diet can support optimal health for pregnant women and have a long-term impact on their offspring. Patients with IBD are already prone to nutrition deficiencies due to factors such as restrictive diets, nutrient loss, drug-nutrient interaction, and decreased absorption from the ileum. Furthermore, reduced oral intake and chronic inflammation increases nutrient needs among IBD patients. Two reports have explored the diets of pregnant women in the Norwegian Mother and Child Cohort (MoBa). The first study found that compared to pregnant women without IBD, pregnant women with IBD were less likely to adhere to a traditional Norwegian dietary pattern characterized by a high intake of lean fish or fish products, potatoes, rice porridge, cooked vegetables, and gravy, and were more likely to adhere to a Western dietary pattern with higher intake of foods and beverages rich in sugar and saturated fats. Moreover, pregnant women with IBD who did adhere to the traditional Norwegian diet had lower odds of having an SGA infant. The second study found that pregnant women with IBD consumed a lower proportion of protein from dairy products compared to pregnant women without IBD. In this case, a reduced intake of protein from dairy was associated with a lower risk of having an SGA infant.

Maternal diet during pregnancy has also been linked to the infant microbiome composition, which is critical for the priming of a balanced immune system during early life. Importantly, it was demonstrated that infants born to women with IBD have less diverse microbiomes and higher levels of fecal calprotectin (a biomarker of intestinal inflammation) compared to the infants of women without IBD. Along with emerging reports demonstrating the mediating role of the gut microbiota in the effectiveness of dietary interventions for IBD management, this finding suggests that improving dietary patterns during pregnancy may beneficially modify the microbiome composition, thereby promoting both maternal and infant health. This hypothesis is being explored by the MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) Trial Diet has been increasingly integrated into IBD management, and studies demonstrate the effectiveness of dietary interventions for inducing IBD remission. In adults, the specific carbohydrate diet (SCD); the Mediterranean diet; the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low FODMAP) diet; and the anti-inflammatory IBD (IBD-AID) diet are among those that have shown efficacy in reducing disease activity and symptoms. Yet, informational resources on nutrition for pregnant women with IBD are sparse. The USDA MyPlate website focuses on a variety of food groups with only broad suggestions of foods and meal plans specific to pregnancy and postpartum needs. The 2014 and 2017 American College of Obstetricians and Gynecologists (ACOG) guideline statements seem focused on nutrients that may be obtained by taking a prenatal vitamin, rather than on whole foods. The 2019 American Gastroenterological Association's Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway report encourages nutrition consultation for specific nutrient deficiency and weight gain patterns in this population, but with few details on compliance to guidelines. In keeping with these publications, pregnant women may hear only general advice from health care providers to take a prenatal vitamin, follow a healthy diet, limit caffeine intake, avoid alcohol and tobacco, and observe caution with seafood. However, while a prenatal vitamin may be recommended in addition to a healthy diet, it cannot supply all the nutrients that are needed to promote healthy and low-risk pregnancies.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

50

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

  • Patients underwent clinical, laboratory, endoscopic, and/or imaging evaluations as part of routine outpatient monitoring.
  • Laboratory investigations (Complete blood picture, Liver function tests, C-reactive protein and ESR, Fecal calprotectin).
  • The following variables were evaluated: age, sex, BMI [weight (kg)/height (m)²], Calories per day, vitamins intake, method of divert, offsprings evaluation ( weight, height, head circumference, growth velocity, lactation evaluation and vitamins intake), history of IBD-related surgeries, current and prior concomitant medications, disease duration

Kuvaus

Inclusion Criteria:

  • All pregnant women and documented IBD diagnosis.
  • The diagnosis of IBD was based on the patient's history supported by clinical, endoscopic and histologic documentation

Exclusion Criteria:

  • Inability to provide informed consent
  • HIV/Aids, multi-fetus pregnancy, fetal chromosomal or structural abnormalities
  • intrauterine growth restriction, active infection (including chorioamnionitis or sepsis), renal disease, or a dietary regime that conflicts with the intervention diet.
  • Pregnant IBD patients who had active perianal or extra-intestinal disease or were treated with antibiotic therapy or steroids at recruitment
  • Women scheduled for C-section prior to week 37

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Dietary Patterns and Diet Quality Among Pregnant Women with Inflammatory Bowel Disease and Their Association with Pregnancy Outcomes and Infant Growth
Aikaikkuna: Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)
This study aims to evaluate dietary patterns and overall diet quality among pregnant women diagnosed with Inflammatory Bowel Disease. It further seeks to examine the relationship between maternal dietary patterns, adherence to pregnancy dietary guidelines, and their impact on perinatal outcomes as well as infant growth. The findings are expected to provide insights into nutritional gaps and inform dietary recommendations for this specific population.
Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Keskiviikko 1. heinäkuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. huhtikuuta 2027

Opintojen valmistuminen (Arvioitu)

Lauantai 1. huhtikuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 24. huhtikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 24. huhtikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 1. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 11. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 5. toukokuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. huhtikuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 04-2026-300837

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa